Harvard College has published compounds reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19).

Rezubio Pharmaceuticals Co. Ltd. has disclosed drug conjugates comprising somatostatin receptor type 5 (SSTR5) antagonists covalently linked to a hydrophilic moiety through a linker reported to be useful for the treatment of type 2 diabetes.

Quantx Biosciences US Inc. has synthesized DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.

Suzhou Puhe Biopharma Co. Ltd. has described apelin receptor (APLNR) agonists reported to be useful for the treatment of idiopathic pulmonary fibrosis, diabetes, obesity, heart failure, hypertension, pulmonary hypertension, sarcopenia and scleroderma.

Evotec International GmbH has divulged NLRP3 inflammasome modulators reported to be useful for the treatment of asthma, rheumatoid arthritis, gout, Crohn’s disease, hypertension, ulcerative colitis, metabolic and neurological disorders, among others.

Bacoba AG has disclosed peptides reported to be useful for the treatment of cancer.

Researchers from Sungkyunkwan University and the Ulsan National Institute of Science and Technology (UNIST) have patented compounds reported to be useful for the treatment of Staphylococcus aureus infections.

Chong Kun Dang Pharmaceutical Corp. has prepared and tested glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of fibrosis, neurodegeneration, nutrition, endocrine, immunological, inflammatory, psychiatric and renal disorders, among others.

The Ohio State University has synthesized DNA topoisomerase II (bacterial) inhibitors reported to be useful for the treatment of bacterial infections.

Aligos Therapeutics Inc. has patented programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment of liver cancer (hepatocellular carcinoma) and hepatitis B.